Sera Prognostics, Inc. (NASDAQ:SERA) Q4 2025 Earnings Call Transcript March 18, 2026 Sera Prognostics, Inc. beats earnings expectations. Reported EPS is $-0.15768, expectations were $-0.18897.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2025 Earnings Call Transcript March 19, 2026 Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were ...
With me on today's call are Relmada Therapeutics, Inc.'s CEO, Dr. Sergio Traversa, who will briefly provide a summary of recent business highlights; Dr. Raj S. Pruthi, Relmada Therapeutics, Inc.'s CMO ...
Some physicians fear this represents the beginning of AI replacing medical judgment. The reality is less dramatic, but more ...
The FDA has released draft guidance that aims to clear up how drug developers can use alternative testing – but that doesn’t mean animal testing in the US is over.
Walk into a primary care clinic today, and you'll notice a shift. Many patients are no longer arriving armed only with Google searches or an open mind. Increasingly, they come with structured, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results